Ora has a proven track record of 19 anti-allergic product approvals from the FDA, EMA, and PMDA over the past 40 years

The development of the next generation of anti-allergic bio-pharmaceuticals will rely on the ability to define the proper clinical and regulatory pathways, coupled with a precise understanding of the proper endpoints, timepoints, and therapy mechanics. At Ora, our approach is to tighten standard deviations through an enhanced level of scientific rigor, the addition of objective assessments, and stringent controls in our models. We study the underlying science of allergic disease, with a specific focus on how potential therapeutic agents may benefit our patients.

Let’s connect! Please fill out the below form or call us at +1 978-685-8900

First Name
Last Name
Email Address
Phone Number
Company Name
Comments (optional)
Please enter the text from the image above: